Cited by 59Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease

Grossberg, George T., Pejović, Vojislav, Miller, Michael L., Graham, Stephen M.·2009·Dementia and Geriatric Cognitive Disorders

Abstract

Memantine is a moderate-affinity, uncompetitive antagonist of N-methyl-D-aspartate receptors, approved for the treatment of moderate to severe Alzheimer's disease (AD). Available data suggest that, in addition to its benefits on cognition, function, and global status, memantine treatment may also help alleviate behavioral symptoms. This article provides an overview of the prevalence, assessment, and treatment of behavioral disturbances in AD, and summarizes current knowledge regarding the effects of memantine on the behavior of community-dwelling patients. We searched EMBASE and PubMed (January 1992 to October 2008) for reports on memantine trials that involved outpatients with moderate to severe AD. All previously unpublished data were obtained from Forest Laboratories, Inc. Behavioral outcomes were assessed in three completed, double-blind, placebo-controlled trials.Overall, patients who received memantine performed better on behavioral measures than those treated with placebo. Post-hoc analyses suggest that memantine treatment was associated with a reduced severity or emergence of specific symptoms, particularly agitation and aggression. Prospective, well-designed trials are warranted to evaluate the efficacy of memantine in patients with significant behavioral symptoms.

Integrity signals

Registry

Crossref · 10.1159/000200013

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In moderate and severe AD, short-term efficacy of memantine monotherapy compared with placebo is reported in several randomized controlled trials of 12 to 50 weeks duration and supported by meta-analyses.

    “In moderate and severe AD, short-term efficacy of memantine monotherapy compared with placebo is reported in several RCTs of 12 to 50 weeks duration and supported by meta-analyses.”

    From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [103]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Grossberg, G. T., Pejović, V., Miller, M. L., & Graham, S. M.
Affiliations
  • Saint Louis University (US)
  • Forest Laboratories (United States) (US)
Venue
Dementia and Geriatric Cognitive Disorders
Publisher
S. Karger AG
Published
2009
Volume
27
Issue
2
Pages
164-172
ISSN
  • 1420-8008 (ISSN-L)
  • 1421-9824
OpenAlex
W2041601072
Cited by
59
References
68
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2023: 1 · 2022: 2 · 2020: 4 · 2019: 6 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 6 · 2014: 4 · 2013: 4 · 2012: 10
FWCI
4.51
Type
journal article
Language
en
Open access
closed
Locations
  • Dementia and Geriatric Cognitive Disorders (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Forest Research Institute
  • Forest Laboratories
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Keywords
memantine, Alzheimer's disease, behavioral symptoms, NMDA receptor antagonists, agitation, aggression, community-dwelling patients, moderate to severe dementia
MeSH terms
Aged, Alzheimer Disease, Behavior, Female, Humans, Male, Memantine, Neuropsychological Tests, Randomized Controlled Trials as Topic, Treatment Outcome, Excitatory Amino Acid Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review